Merck receives complete response letter from U.S. FDA for investigational medicine ridaforolimusr
Ridaforolimus is an investigational oral mTOR inhibitor...
5 June 2012 | By Merck
Ridaforolimus is an investigational oral mTOR inhibitor...
List view / Grid view
Ridaforolimus is an investigational oral mTOR inhibitor...
5 June 2012 | By Merck
Ridaforolimus is an investigational oral mTOR inhibitor...
"Merck remains confident in the potential of the investigational agent…
20 March 2012 | By Merck
"Merck remains confident in the potential of the investigational agent ridaforolimus..."
Merck and ARIAD Pharmaceuticals, Inc., announced the presentation of detailed…
6 June 2011 | By Merck
Merck and ARIAD Pharmaceuticals, Inc., announced the presentation of detailed results from the Phase III SUCCEED clinical trial...